+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-10-15Number of Pages: 104

Thyroid Gland Disorders Treatment Market (By Disorders - Hypothyroidism and Hyperthyroidism) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

Thyroid gland is made of thyroid cells that absorb iodine from food and convert it into triiodothyronine (T3) and thyroxine (T4). These hormones are released into the blood stream and play an important role in the regulation of metabolism. Thyroid gland disorders are defined as an abnormal release of thyroid hormones which may demand proper therapeutic agents to correct the disorder condition. This report studies the market in a view of different types of thyroid drugs i.e. hypothyroid drugs and hyperthyroid drugs. The report comprises an elaborate executive summary, which includes a market snapshot that provides market dynamics of various segments and sub-segments that are included in the report in a precise manner. Moreover, executive summary comprises waterfall diagram, which reflects the market size of various segments in the descending order.

A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global thyroid gland disorders treatment market and future opportunities has been provided in the market overview section. This section of the report also provides with market attractiveness analysis, epidemiology study, event impact analysis, regulatory framework and market share analysis by key players (%) operating in the thyroid gland disorders treatment market. 

Based on disorders, the global thyroid gland disorders treatment market has been segmented into hypothyroidism and hyperthyroidism. The market for these types has been extensively analyzed for different thyroid gland disorders drugs based on sales revenue of the various generic and branded products developed by the manufacturers. The market size and forecast in terms of USD million for each disorder has been provided for the period from 2013 to 2023. The report on the thyroid gland disorders treatment market also provides with compounded annual growth rate (CAGR %) for each of the market segments mentioned above with the forecast period from 2015 to 2023, considering 2014 as the base year.

Geographically, the thyroid gland disorders treatment market has been categorized into North America, Europe, Asia-Pacific, Latin America, the Middle East and North Africa (MENA) and Rest of the World (RoW) which are further divided based on the disorder types i.e. hypothyroidism and hyperthyroidism. Asia Pacific, further comprises detailed country analysis for China and Rest of APAC. Likewise, Latin America extensively provides with the detailed countrywise analysis for Brazil and Rest of LATAM. The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2013 to 2023 along with CAGR (%) for the forecast period from 2015 to 2023. The research study also incorporates the competitive scenario of major players in these regions.

A list of recommendations has been provided for new entrants to help establish a strong presence and for existing market players to increase their market shares. The report concludes with the profiles of the major players in the thyroid gland disorders treatment market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Major players profiled in this report include Abbott Laboratories, Lannett Company, Inc., Pfizer, Inc., Merck KGaA, and Mylan N.V. 

 
The global thyroid gland disorders treatment market is segmented as follows

  • Global Thyroid Gland Disorders Treatment Market, by Disorders
    • Hypothyroidism
      • Levothyroxine
      • Liothyronine
    • Hyperthyroidism
      • Imidazole
      • Propacil
  • Global Thyroid Gland Disorders Treatment Market, by Geography
    • North America
      • Hypothyroidism
      • Hyperthyroidism
    • Europe
      • Hypothyroidism
      • Hyperthyroidism
    • Asia Pacific
      • Asia Pacific (APAC), by Disorders
        • Hypothyroidism
        • Hyperthyroidism
      • Asia Pacific (APAC), by Country
        • China
          • Hypothyroidism
            • Levothyroxine
            • Liothyronine
          • Hyperthyroidism
            • Imidazole
            • Propacil
        • Rest of APAC
          • Hypothyroidism
            • Levothyroxine
            • Liothyronine
          • Hyperthyroidism
            • Imidazole
            • Propacil
    • Latin America (LATAM)
      • Latin America, by Disorders
        • Hypothyroidism
        • Hyperthyroidism
      • Latin America, by Country
        • Brazil
          • Hypothyroidism
            • Levothyroxine
            • Liothyronine
          • Hyperthyroidism
            • Imidazole
            • Propacil
        • Rest of LATAM
          • Hypothyroidism
            • Levothyroxine
            • Liothyronine
          • Hyperthyroidism
            • Imidazole
            • Propacil
  • Middle East and North Africa (MENA)
    • Hypothyroidism
    • Hyperthyroidism
  • Rest of the World (RoW)
    • Hypothyroidism
    • Hyperthyroidism


Chapter 1 Preface
1.1 Overview
1.2 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 Assumptions

Chapter 2 Executive Summary
2.1 Thyroid Gland Disorders Treatment Market: Market Snapshot
2.2 Global Thyroid Gland Disorders Treatment Market Revenue, by Disorder, 2014 (US$ Mn)
2.3 Global Thyroid Gland Disorders Treatment Market Revenue, by Drug Class, 2014 (US$ Mn)
2.4 Global Thyroid Gland Disorders Treatment Market Share, by Geography (Value %) Year is missing here

Chapter 3 Industry Analysis
3.1 Introduction
3.2 Epidemiology: Thyroid Gland Disorders
      3.2.1 Disease Background
      3.2.2 Risk Factors and Comorbidities
      3.2.3 North America Age and Gender Specific Prevalent Cases
      3.2.3 Europe Age and Gender Specific Prevalent Cases
      3.2.3 Asia Pacific and Latin America Age and Gender Specific Prevalent Cases
      3.2.3 Rest of the World Age and Gender Specific Prevalent Cases
3.3 Market Dynamics
      3.3.1 Market Drivers
             3.3.1.1 Increasing incidence of thyroid gland disorders expected to propel the market
             3.3.1.2 Rise in obese, diabetic, and cardiovascular patients is expected to increase the risk for thyroid disorders, thereby driving demand for thyroid drugs
             3.3.1.3 Growing disease awareness programs in developing regions
      3.3.2 Market Restraints
             3.3.2.1 Rising customer preference for alternative treatments
             3.3.2.2 Asymptomatic nature of thyroid disorders lead to large undiagnosed population
      3.3.3 Market Opportunities
             3.3.3.1 Expand footprint in emerging nations that offer sustained growth opportunities
3.4 Regulatory Framework: Global Thyroid Gland Disorders Treatment Market
3.5 Event Impact Analysis: Global Thyroid Gland Disorders Treatment Market
3.6 Market Attractiveness Analysis: Global Thyroid Gland Disorders Treatment Market
3.7 Company Market Share – Global Thyroid Gland Disorders Treatment Market (2014) (%) 

Chapter 4 Market Segmentation, by Disorders
4.1 Introduction
4.2 Global Thyroid Gland Disorders Treatment Market Revenue, by Disorder, 2013–2023 (US$ Mn)
4.3 Global Hypothyroidism Treatment Market Revenue, by Drug, 2013–2023 (US$ Mn)
      4.3.1 Global Levothyroxine Market Revenue, 2013–2023 (US$ Mn)
      4.3.2 Global Liothyronine Market Revenue, 2013–2023 (US$ Mn)
4.4 Global Hyperthyroidism Market Revenue, by Drugs, 2013–2023 (US$ Mn)
      4.4.1 Global Imidazole Market Revenue, 2013–2023 (US$ Mn)
      4.4.2 Global Propacil Market Revenue, 2013–2023 (US$ Mn)

Chapter 5 Market Segmentation, by Geography
5.1 Thyroid Gland Disorders Treatment Market Revenue, by Geography, 2013–2023 (US$ Mn)
5.2 North America Thyroid Gland Disorders Treatment Market Revenue, by Disorder, 2013–2023 (US$ Mn)
5.3 Europe Thyroid Gland Disorders Treatment Market, by Disorder, 2013–2023 (US$ Mn)
5.4 Asia Pacific Thyroid Gland Disorders Treatment Market Revenue, by Disorder, 2013–2023 (US$ Mn)
5.5 Asia Pacific Thyroid Gland Disorders Treatment Market Revenue, by Country, 2013–2023 (US$ Mn)
      5.5.1 China Thyroid Gland Disorders Treatment Market Revenue, by Disorder, 2013–2023 (US$ Mn)
             5.5.1.1 China Hypothyroidism Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
             5.5.1.2 China Hyperthyroidism Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
      5.5.2 Rest of APAC Thyroid Gland Disorders Treatment Market Revenue, by Disorder, 2013–2023 (US$ Mn)
             5.5.2.1 Rest of APAC Hypothyroidism Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
             5.5.2.2 Rest of APAC Hyperthyroidism Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
5.6 Latin America Thyroid Gland Disorders Treatment Market, by Disorder, 2013–2023 (US$ Mn)
5.7 Latin America Thyroid Gland Disorders Treatment Market, by Country, 2013–2023 (US$ Mn)
      5.7.1 Brazil Thyroid Gland Disorders Treatment Market Revenue, by Disorder, 2013–2023 (US$ Mn)
            5.7.1.1 Brazil Hypothyroidism Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
            5.7.1.2 Brazil Hyperthyroidism Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
      5.7.2 Rest of LATAM Thyroid Gland Disorders Treatment Market Revenue, by Disorder, 2013–2023 (US$ Mn)
            5.7.2.1 Rest of LATAM Hypothyroidism Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
            5.7.2.2 Rest of LATAM Hyperthyroidism Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
5.8 MENA Thyroid Gland Disorders Treatment Market, by Disorder, 2013–2023 (US$ Mn)
5.9 RoW Thyroid Gland Disorders Treatment Market, 2013–2023 (US$ Mn)

Chapter 6 Recommendations
6.1 Increase in research and development activities
6.2 Emphasis on spreading awareness about the disorders as well as promotional campaigns
6.3 Development of effective combination thyroid drug therapy

Chapter 7 Company Profiles
7.1 Abbott Laboratories
7.2 AbbVie, Inc. 
7.3 Allergan plc
7.4 GlaxoSmithKline plc
7.5 Pfizer, Inc.
7.6 Lannett Company, Inc.
7.7 Merck KGaA
7.8 Mylan N.V.
7.9 Novartis International AG
7.10 Sanofi
7.11 Takeda Pharmaceutical Company Ltd.

Hormones produced by thyroid gland are vital for stimulating growth, metabolism and calories processing. Underactive or overactive thyroid is commonly found in women than men and is termed as thyroid gland disorder. The global thyroid gland disorders treatment market is promises a decent growth attributed by the rising prevalence of both hyperthyroidism and hypothyroidism across the globe. Furthermore, the expanding pool of geriatric population, sedentary lifestyle and consistent initiatives by the key market players to introduce innovative therapeutic options account as key influencers for the growth of thyroid gland disorders treatment market. It is noticeable that preference of patients for alternative treatment therapies such as thyroid surgery is expected to hinder market growth.

 

Globally, thyroid gland disorders (thyroid nodules, hypothyroidism, and hyperthyroidism) affect around 5% to 10% of the population. Hypothyroidism and hyperthyroidism affect majority of the population primarily due to increasing incidence of autoimmune diseases such as Hashimoto's thyroiditis and Grave’s disease. Additionally, iodine deficiency, a widespread problem across the world, is considered a prime risk factor for the increase in prevalence of thyroid disorders. Based on disorder, the thyroid gland disorders treatment market has been primarily categorized into two segments: hypothyroidism and hyperthyroidism. The hypothyroidism segment includes drugs such as Levothyroxine and Liothyronine. The hyperthyroidism segment covers drugs such as Imidazole and Propacil. The thyroid gland disorders treatment market is expanding at a strong growth rate primarily due to rise in thyroid disorder patient population globally, increase in
demand for drugs for hypothyroidism such as Synthroid and Euthyrox in developed and developing regions, and consistent efforts by leading thyroid drug manufacturers to develop breakthrough therapeutics. However, availability of numerous generic formulations has led to a decline in the overall market revenue.

 

Based on geographic distribution, North America is the largest market for thyroid gland disorders treatment. For instance, a study conducted by the National Health and Nutrition Examination Survey in July 2012 evaluated that the prevalence of hypothyroidism varies from 4.6% to 9.5% of the population of the U.S. every year.High prevalence of thyroid gland disorders, better awareness among general public, better availing of diagnosis and treatment modules coupled with favorable reimbursements together define the dominance of North America market. On the other hand, Asia Pacific market will register the fastest market growth in terms of sales of thyroid gland disorders drugs during the given forecast period. Countries such as India, China, Japan and Malaysia together determine the market trends in Asia pacific. Large consumption of generic formulations across these countries contribute to the growth of the market, mitigating the lower sales revenue in the region. Recent growth in investments and awareness initiatives by the market incumbents also contribute to the market growth in the region. 

 

Abbott Laboratories, AbbVie, Inc., Mylan N.V., Pfizer, Inc., GlaxoSmithKline plc, Merck KGaA, Novartis AG, Sanofi and others are some of the key players having presence in the global thyroid gland disorders market. The global thyroid gland disorders treatment market is consolidated, with relatively small number of companies accounting for a majority share of the market. In 2014, the thyroid gland disorders treatment market was dominated by AbbVie, Inc. and Merck KGaA, collectively accounting for more than half share of the market.

thyroid-gland-disorder-2015market.png

 


A complete brochure for this research is available for download.

Interact with our pool of experienced analysts for any report related queries